Cathepsin-k expression in pulmonary lymphangioleiomyomatosis.

Department of Pathology, University of Verona, Verona, Italy.
Modern Pathology (Impact Factor: 6.36). 01/2009; 22(2):161-6. DOI: 10.1038/modpathol.2008.189
Source: PubMed

ABSTRACT Lymphangioleiomyomatosis is a rare and progressive lung cystic disease, caused by the infiltration of lung parenchyma by mesenchymal cells characterized by co-expression of contractile proteins and melanocytic markers. The pathogenesis of lymphangioleiomyomatosis is determined by mutations affecting tuberous sclerosis complex (TSC) genes, with eventual deregulation of the Rheb/mTOR/p70S6K pathway, and the potential therapeutic activity of mTOR inhibitors is currently under investigation. To better understand the molecular mechanisms involved in the pathogenesis of lymphangioleiomyomatosis, we investigated the expression of cathepsin-k (a papain-like cysteine protease with high matrix-degrading activity). The rationale of this choice was based on the recent demonstration that mTOR inhibitors can regulate major functional activities of osteoclasts, including the expression of cathepsin-k. The immunohistochemical study included 12 cases of lymphangioleiomyomatosis. Twelve angiomyolipomas and several lung diseases (sarcoidosis, organizing pneumonia, usual interstitial pneumonia, emphysema) were investigated as controls. In all lymphangioleiomyomatosis cases, strong cathepsin-k immunoreactivity was demonstrated, restricted to lymphangioleiomyomatosis cells. Similar expression levels were observed in renal angiomyolipomas. These observations extend the knowledge regarding the immunophenotypic profile of lymphangioleiomyomatosis cells, and provide a useful new marker for diagnosis in difficult cases (eg, in small transbronchial biopsies). The strong expression of such a potent papain-like cysteine protease in lymphangioleiomyomatosis cells can significantly contribute to the progressive remodelling of lung parenchyma observed in this deadly disease, with eventual formation of lung cysts. It is possible to speculate that mTOR inhibitors may exert part of their action by limiting the destructive remodelling of lung structure.

Download full-text


Available from: Maurizio Pea, Jul 20, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is now growing evidence that lung cysteine cathepsins take part in several biological processes and pulmonary homeostasis, although their exact functions remain to be clarified. Their production is increased in most tumors and in chronic and acute inflammatory lung disorders such as silicosis, COPD (emphysema, chronic bronchitis), asthma, and bronchopulmonary dysplasia. Cathepsins aggravate the extent and severity of inflammation and contribute to the remodeling and/or degradation of the extracellular matrix and the basement membrane. Cysteine cathepsins and their inhibitors (stefins and cystatins) are both potential markers of the prognosis and diagnosis of cancer. Cathepsin S is a potential marker of asthma, while cathepsin K may be a useful immunohistological marker of lymphangioleiomyomatosis and of granulomas in interstitial lung diseases. This review covers selected aspects of our current knowledge about lung cysteine cathepsins and outlines some recent advances. We also examine the implications of using cathepsin inhibitors to treat a variety of bone and joint diseases like rheumatoid arthritis, osteoporosis, and bone metastasis for the risk of deleterious side effects on the lungs. KeywordsArthritis–Asthma–Bone disease–Cathepsin–Chronic obstructive pulmonary disease–Cysteine protease–Emphysema–Fibrosis–Osteoporosis–Protease inhibitor
    Clinical Reviews in Bone and Mineral Metabolism 06/2011; 9(2):148-161. DOI:10.1007/s12018-011-9094-6
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, a decomposition method is proposed which relates the unit ramping process to the cost of fatigue effect in the generation scheduling of thermal systems. The objective of this optimization problem is to minimize the system operation cost, which includes the fuel cost for generating the required electrical energy and starting up decommitted units, as well as the rotor depreciation during ramping processes, such as starting up, shutting down, loading, and unloading. According to the unit fatigue index curves provided by generator manufacturers, fixed unit ramping-rate limits, which have been used by previous studies, do not reflect the physical changes of generator rotors during the ramping processes due to the fatigue effect. By introducing ramping costs, the unit on/offstates can be determined more economically by the proposed method. The Lagrangian relaxation method is proposed for unit commitment and economic dispatch, in which the original problem is decomposed into several subproblems corresponding to the optimization process of individual units. The network model is employed to represent the dynamic process of searching for the optimal commitment and generation schedules of a unit over the entire study time span. The experimental results for a practical system demonstrate the effectiveness of the proposed approach in optimizing the power system generation schedule
    IEEE Transactions on Power Systems 03/1995; 10(1-10):60 - 67. DOI:10.1109/59.373928 · 3.53 Impact Factor
Show more